<DOC>
	<DOCNO>NCT01175941</DOCNO>
	<brief_summary>This study examine effect alpha adrenergic stimulation anal canal rectum parameter affect control defecation subject faecal incontinence . The study investigate effect rectal suppository contain 10 mg NRL001 give seven day , daily . Rectal compliance median anal resting pressure consider primary objective study . A pharmacokinetic evaluation plus safety tolerability assessment include monitoring electrocardiogram ( ECGs ) , blood pressure heart rate also evaluate secondary objective .</brief_summary>
	<brief_title>Effect 7 Days Dosing With 10 mg Rectal Suppository NRL001in Patients With Faecal Incontinence</brief_title>
	<detailed_description />
	<mesh_term>Fecal Incontinence</mesh_term>
	<criteria>Male female patient volunteer age 40 85 year without clinically significant uncontrolled cardiovascular , renal hepatic disease ( determined medical history , physical examination , laboratory test value , vital sign , electrocardiograms [ ECGs ] screen ) Patients mild/moderate passive faecal incontinence base clinical symptomology demonstrate follow criterion : ARP ≥20mmHg ≤80mmHg Intact IAS demonstrate endoanal ultrasound Rectal capacity ≥150ml Cleveland Clinic Score ≥6 ≤ 15 Body mass index ( BMI ) ≥ 16 ≤ 32 Able willing receive rectal treatment Able voluntarily provide write informed consent participate study Must understand purpose risk study agree follow restriction schedule procedure define protocol Female volunteer must either postmenopausal ( least one year confirm serum FSH screening ) , surgically sterile , practise true sexual abstinence , use Investigatorapproved method contraception throughout study post study physical examination negative pregnancy test screening Must willing consent data enter The OverVolunteering Prevention System Patients FI related anatomical and/or traumatic sphincter defect Presence significant uncontrolled cardiovascular , pulmonary , hepatic , renal , immunologic , neurological psychiatric disease Concomitant anorectal condition disease assess potentially interfere study medication Investigator ( e.g . concomitant haemorrhoid , anal fissure ) . Conditions consider interfere study medication allow Clinically relevant ECGabnormalities evident QTc prolongation and/or acute arrhythmia Current history drug alcohol abuse Use disallow concomitant medication , include overthecounter item within 30 day prior study drug administration end study Use medication last 30 day apply via rectum Use medication currently within last 30 day investigator believe may affect study participation result Unstable regimen statin , hypertensive diuretic medication ( patient volunteer must stable regimen least 2 month ) Participation clinical drug study 90 day precede initial dose study History allergy nifedipine alphaadrenoceptor antagonist latex Consumption alcoholic beverage within 24 hour prior dose Patient volunteer consider competent consent trial score le 25 MMSE® Volunteers , opinion Investigator , unsuitable participation study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>